02/10/2014 12:35:10 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
10/01/201410:00AMBWBristol-Myers Squibb to Announce Results for Third Quarter on October 24
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter on Friday, October 24, 2014. During a conference call at 10:30 a.m. EDT on October 24, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited... More...>>
10/01/20149:47AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Amazon.com Inc. (AMZN), RCS Capital Corp. (RCAP) and Babcock & Wilcox Co. (BWC). Amazon.com appears to be close to settling a nearly two-month dispute with Walt Disney Co. (DIS) during which the e-commerce giant stopped offering Disney... More...>>
09/30/20145:00PMBWBristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential
Transfers liabilities and related assets for approximately 8,000 U.S. retirees and their beneficiaries Benefits entrusted to a global financial institution with expertise in long-term management of retirement benefits Bristol-Myers Squibb Company (NYSE:BMY) today announced it will settle $1.4 billion in pension obligations... More...>>
09/29/20148:21AMBWEuropean Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer
First completed regulatory submission for a PD-1 immune checkpoint inhibitor in lung cancer Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the... More...>>
09/29/20143:00AMBWPositive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presen...
Objective response rate was 32% in Opdivo treated patients and 11% in the reference arm of chemotherapy-treated patients Majority (95%) of responses were ongoing in Opdivo treated patients and median duration of response was not reached Overall frequency of adverse events was lower with Opdivo compared to chemotherapy;... More...>>
09/26/20144:18PMBWBristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union
FDA accepts for priority review the Biologics License Application for previously treated advanced melanoma, based on data from first Phase 3 randomized trial of a PD-1 immune checkpoint inhibitor; agency grants second breakthrough therapy designation for Opdivo European Medicines Agency validates the marketing authorization... More...>>
09/22/20148:00AMBWBristol-Myers Squibb & Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for P...
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease. The donations will fund the independent development of innovative... More...>>
09/16/20144:30PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October... More...>>
09/16/20145:59AMPRNCASanté Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome m...
Santé Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome métastatique, la forme la plus mortelle de cancer de la peau Canada NewsWire MONTRÉAL, le 16 sept. 2014 Cette immunothérapie associée à une survie à long terme chez des... More...>>
09/16/20145:59AMPRNCAHealth Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly for...
Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer Canada NewsWire MONTREAL, Sept. 16, 2014 Immunotherapy treatment with long-term survival in some previously treated patients now approved for use in newly diagnosed patients... More...>>
09/11/201410:00AMBWBristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Thursday, September 18, 2014, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 9:45 a.m. (BST), 4:45 a.m... More...>>
09/04/20143:30PMDJNFDA Approves Merck's Cancer Drug
U.S. regulators on Thursday approved a new kind of cancer drug from Merck & Co. that is designed to unleash the body's immune system against tumors and could generate billions of dollars in sales. The drug, which Merck plans to sell under the brand name Keytruda, is part of a long-anticipated wave of medicines that... More...>>
09/02/201410:58AMBWBristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2014 Global Health Care Conference on Monday, September 8, 2014, in New York. Giovanni Caforio, chief operating officer, will answer questions about the company at 2 p.m. EDT. Investors and the general public are invited to listen to a live webcast... More...>>
08/30/20145:15AMBWSecondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Signi...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated... More...>>
08/27/20144:40PMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Express Inc. (EXPR), Michaels Cos. (MIK) and Smith & Wesson Holding Corp. (SWHC). Brown Shoe Co. (BWS) said its fiscal second-quarter profit rose 18% as its wholesale business and Famous Footwear chain reported higher sales. The company's... More...>>
08/27/20145:00AMBWEuropean Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of C...
Daklinza, when used in combination with sofosbuvir, is an all-oral, once daily regimen that yields cure rates of up to 100% Daklinza + sofosbuvir offers potential cure for a broad range of EU HCV patients, including those with advanced liver disease, genotype 3 and protease inhibitor failures Bristol-Myers Squibb Company (NYSE:BMY... More...>>
08/21/20141:31PMBWU.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE), & for the Red...
Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the AMPLIFY trial Eliquis demonstrated superiority in the primary safety endpoint of major bleeding versus enoxaparin/warfarin in the AMPLIFY trial... More...>>
08/20/20148:00AMBWBristol-Myers Squibb & Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy & Chemotherapy Combination Re...
Phase I study to evaluate OPDIVO (nivolumab), Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with Celgene’s ABRAXANE® for multiple cancers Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (Nasdaq:CELG) announced today the establishment of a clinical trial collaboration to evaluate... More...>>
08/20/20148:00AMBWBristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014
Fourteen abstracts to be presented, including new analyses from the ARISTOTLE®, AMPLIFY® and AMPLIFY-EXT trials evaluating patients with nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world... More...>>
08/07/201411:00AMPRNUSLeica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnost...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies PR Newswire NUSSLOCH, Germany, August 7, 2014 NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ -- Leica Biosystems announces a collaboration with Bristol-Myers Squibb... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy141002 12:35